Date:2/19/2009

ical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In particular, there can be no assurance that bazedoxifene will be commercially successful or that bazedoxifene will be approved in the future in other formulations or indications and/or in other countries, including the United States. Other risks and uncertainties include, without limitation, the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the
'/>"/>

SOURCE Wyeth Pharmaceuticals Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4
Related medicine news :

1. Osteotech Receives 13485:2003 ISO Certification; Company Meets International Standards for Medical Device Manufacturing
2. Cipher receives tentative FDA approval for extended-release tramadol capsules
3. China Shenghuo Receives Notice from NYSE Alternext US Regarding Listing Standards
4. A Drug That Receives Regulatory Approval for Cognitive Impairment Associated With Schizophrenia Would Earn a Higher Patient Share in the United States Than in Europe
5. i.HUG Foundation Receives International Grant: Hires a School Nurse to Improve Student Health and Learning
6. Emageon Receives Escrowed Funds and Terminates Merger Agreement
7. Children's National Medical Center Trauma Center Receives Highest Verification from American College of Surgeons
8. Abbott Receives FDA Clearance for New CELL-DYN(R) Emerald(TM) Hematology Instrument
9. Rising Medical Solutions Receives URAC Workers Compensation Utilization Management Accreditation
10. Executive Board Member of National Patient Advocate Foundation, Patient Advocate Foundation Receives National Institutes of Health 2008 Health Disparities Excellence Award
11. Nationwide Receives IBI/NBCH Healthy Workforce Productivity Award